The joint development project of Protagonist Therapeutics and Johnson & Johnson (NYSE:JNJ) produced Icotrokinra as their ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.

GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Results from the phase 3 ICONIC-LEAD study presented at this year’s American Academy of Dermatology (AAD) annual meeting ...

Protagonist Therapeutics shares were up 28% to $49.25 after the company reported positive topline results from a Phase 2b study of icotrokinra, conducted by partner Johnson & Johnson.

We recently compiled a list of the 10 Firms Buck Market Bloodbath on Monday. In this article, we are going to take a look at ...

H.C. Wainwright raised the firm’s price target on Protagonist Therapeutics (PTGX) to $80 from $54 and keeps a Buy rating on the shares. The ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...